Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1941 - The gelatinases-stimuli nanoparticles reverse docetaxel resistance and epithelial to mesenchymal transition in lung cancer cell line


10 Oct 2016


Poster display


Qin Liu


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


Q. Liu1, R. Li2, H. Qian2, B. Liu2

Author affiliations

  • 1 The Comprehensive Cancer Center, Affiliated Drum Tower Hospital Nanjing University, 210008 - Nanjing/CN
  • 2 The Comprehensive Cancer Center, Affiliated Drum Tower Hospital Nanjing University, Nanjing/CN


Abstract 1941


Drug resistance is a main obstacle for the successful cancer therapy. Emerging evidence suggests that miR-200c functions as an effective cancer stem cells (CSCs) inhibitor and restores sensitivity to microtubule-targeting drugs.


In the present work, we engineered the intelligent gelatinases-stimuli nanoparticles (NPs) to co-delivery miR-200c and antitumor drug docetaxel (DOC) to verify their synergetic effects on inhibition of CSCs and cancer cells. After tumor cells were treated with miR-200c NPs, miR-200c and its targeted gene class III beta-tubulin (TUBB3) expression were evaluated. The effects of (miR-200c + DOC) NPs on DOC-resistant lung cancer cells viability as well as the expression of E-cadherin and CD44 were studied.


We found that the (miR-200c + DOC) NPs significantly overcome DOC resistance, possibly by elevated miR-200c expression,low TUBB3 level, and reversed the EMT through upregulation E-cadherin and inhibition lung CSCs.


The (miR-200c + DOC) NPs may provide a new modality for co-delivery of nucleic acid and drugs to inhibit CSCs and reverse drug resistance.

Clinical trial identification

Legal entity responsible for the study

Qin Liu


The National Nature Science Foundation of China (81302053)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings